The Collaborative Fund of the CGA was created in 2012 to provide a funding mechanism for projects that support the mission of the CGA-IGC.
Below is a description of the Collaborative Fund including details on eligibility, submission instructions, and deadline information. To download the Word version of the "Call for Proposals," click here.
The Collaborative Fund of the CGA is supported by the members of the CGA and through the generous, unrestricted matching grants of our industry sponsors.
COLLABORATIVE FUND OF THE CGA - CALL FOR PROPOSALS
The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) is offering research or project awards that directly promote the mission of the organization. Proposals submitted for consideration should address one or more of the following:
1. To educate physicians and other healthcare professionals in the identification, molecular genetics and clinical management of inherited gastrointestinal cancer.
2. To enable or provide a mechanism of communication for the dissemination or exchange of data, discussion of controversial areas involved in the care of patients and their families with inherited gastrointestinal cancer syndromes.
3. To facilitate collaborative studies involving multiple institutions that focus on inherited gastrointestinal cancer.
4. To improve identification and care of patients at increased risk for gastrointestinal cancer and address issues concerning patients and families with inherited syndromes.
5. To improve multidisciplinary expertise in clinical care, healthcare policy and research related to inherited gastrointestinal cancer.
Award of up to $10,000 for 1 year will be given to unique and creative projects based on competitive review. Preliminary or pilot projects do not necessarily require previous work or preliminary data. These awards are not designed to fund existing or ongoing activities. Grants submitted with matching funds will receive special attention. Each award will be for one year; however, a no-cost extension may be considered with appropriate justification and approval by the Collaborative Fund Committee of the CGA-IGC.
The proposed research or activity must be investigator-initiated and conducted within North, Central or South America
The principal investigator/author must be a member in good standing of CGA-IGC at the time of grant submission
All active members of the CGA-IGC, regardless of the degree or title, are encouraged to submit
Members of the CGA-IGC Executive Council or Collaborative Fund Committee, are ineligible for receiving funding from this award
Investigators may submit one application per funding cycle
The awarding of a grant, or renewal of an existing grant, is at the discretion of the Collaborative Fund Committee and can be suspended from year to year
The scope of the proposed research should match the grant budget. All or part of a submitted proposal cannot be funded by another institution or agency, either local or national other than in the form of a matching grant.
The submitting investigator agrees to complete the project based on the specific aims and budget submitted. Changes in specific aims or scope of the proposed project may be allowed with appropriate justification and approval by the CGA-IGC.
Salary support for the investigator(s), travel funds or institutional indirect costs are not allowed
A progress report will be submitted at the end of the sixth month of funding to the Collaborative Fund Committee with a final report being submitted within three months of completion of the grant period
Successful applicants must agree to acknowledge CGA-IGC Collaborative Fund support in any publications or presentations that result from the research or project, with the following text: “Supported by the Collaborative Fund of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.”
All awards will be recognized at the annual meeting. One or more of the investigators participating in the project are required to present their findings or outcomes of the project to the CGA-IGC membership at the annual meeting. To facilitate this presentation, the principal investigator or their designate will be offered complementary meeting registration for the meeting in which they present their project.
Application Deadline: Completed applications (as defined below) must be received by 5:00PM EST on Friday, September 10, 2021.
In evaluating the merits of an application, the Committee will consider the following:
The nature and clarity of the project as a discrete, well defined activity that can be completed within the proposed study period
Clinical or scientific significance or relevance of the project as it pertains to the field of inherited colorectal cancer syndromes
Overall impact of the proposal (e.g. number of individuals or institutions that will benefit)
Availability of other resources to fund the proposal
Ability of the investigator(s) to complete the Specific Aims or objectives of the proposal
Project feasibility (including availability of adequate resources, personnel, and facilities) and measures of outcome
Instructions for Submission:
Applications are required to include the following elements. Documents should be formatted using 1” margins and a font no smaller than 11 point with a limit of 10 pages TOTAL.
FAILURE TO ADHERE TO THESE INSTRUCTIONS MAY CAUSE THE GRANT APPLICATION TO BE RETURNED WITHOUT REVIEW.
Application Deadline: Completed applications must be received by 5:00PM EST on Friday, September 10, 2021.
Applications can be submitted by E-mail as a PDF with signature sheets by mail or email.
E-mail submissions: firstname.lastname@example.org
Mail: Elena M. Stoffel, MD, MPH
Director, Cancer Genetics Clinic
University of Michigan
2150A Cancer Center
1500 E. Medical Center Dr.
Ann Arbor, MI 48109
ALL sections below are counted in the 10 page limit
Cover Page See attached face sheet
Background/Significance, Hypothesis, and Specific Aims
Briefly review background material for the proposal while critically evaluating existing knowledge, and present the significance of the topic. Clearly and concisely state the hypothesis to be tested and what the project is intended to accomplish.
Research Plan (maximum 3 pages)
This includes why the project is important and specifics of how this proposal promotes the mission of the CGA and who will benefit from the project
Project or Experimental Design-
Description of the study design as well as primary and secondary Measurable Outcomes and a timeline covering the period of funding
That includes interpretation of possible outcomes that includes a description of outcome measurements used to assess the success of the project
Strengths and Weaknesses-
This should include pitfalls and alternative approaches
Resources Available and Feasibility to complete the project/research-including institutional support for the project
List all citations of literature at the end of the research plan, in the order in which they are cited in the proposal. Each complete citation must include the names of first three authors, the complete title of any article, the name of the book or journal, volume number, page numbers, and year of publication.
Institutional Review Board (IRB) status- If the proposal involves the participation of human subjects, this section MUST include either a draft of the consent form or the IRB-approved study consent forms; or (if applicable) institutional review board approval for the use of human subjects. Please note IRB approval is required before release of funding, but IRB approval is not required at the time of proposal submission.
Conflict of interest-all applications should consider and address conflict of interest issues regarding copyright materials (device and drug patents)
A proposal budget should be prepared as a separate document. Indicate how the funds will be allocated and justify each budget item.
The Sections below items are excluded from the 10 page limit
A letter of support from the home sponsoring institution is needed that should describe the necessary administrative and other assistance they are willing to provide including time and financial support to present project results at the CGA-ICC national meeting. As mentioned previously, complementary registration will be offered to the Principal Grant Applicant to facilitate their participation in the CGA national meeting.
Provide letters of support from all collaborators particularly if multiple institutions are involved.
Biographical Sketch for Primary Investigator and Co-investigators (NIH format), including current and pending other support.
We wish to acknowledge our Platinum Corporate Sponsor Promega.